Most Read Articles
6 days ago
Ofatumumab appears to be effective and well-tolerated in the treatment of patients with long-standing systemic lupus erythematosus, offering an alternative to the B cell–depleting agent rituximab, according to a study.
13 Apr 2018
A recent study has shown that the herpes zoster (HZ) vaccine induces varicella zoster virus (VZV)-specific cellular and humoral responses in patients with rheumatic arthritis (RA).
15 Apr 2018
Compared to other tumour necrosis factor–α inhibitors (TNFi), infliximab remains superior in reducing Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at 12 weeks, results of a network meta-analysis (NMA) have shown. However, it was sensitive to inclusion of an open-label trial, and its efficacy faded at 24 weeks.

Ofatumumab a safe, effective alternative in B cell–depletion therapy

6 days ago

Ofatumumab appears to be effective and well-tolerated in the treatment of patients with long-standing systemic lupus erythematosus (SLE), offering an alternative to the B cell–depleting agent rituximab, according to a study.

The single-centre study included 16 patients who received ofatumumab, with 50 percent having prior exposure to cyclophosphamide and rituximab (median cumulative dose, 4 g). However, two patients were unable to complete treatment due to significant infusion reactions to ofatumumab, and were therefore excluded from the analysis.

Of the 14 patients (median age 34 years; median duration of SLE, 9.2 years), 12 achieved B cell depletion with ofatumumab. Indications were lupus nephritis (LN) in 12 patients, extra-renal flare in one and remission maintenance in the remaining patient. Treatment was associated with improvements in serological markers of disease activity, including antinuclear antibody, antidouble stranded DNA antibody and complement levels.

In the subgroup of patients treated for LN, half showed response and achieved renal remission by 6 months. Of the six nonresponders, one was retreated with ofatumumab and subsequently achieved remission, while the remaining five had progressive disease that was unresponsive to augmented immunosuppression with cyclophosphamide.

During a median follow-up of 28 months, five grade III infections were documented. No malignancies or deaths occurred.

According to researchers, ofatumumab is a potential alternative in patients who are intolerant of rituximab, with the drug proving to be safe and effective at inducing B cell depletion, with subsequent clinical responses.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Ofatumumab appears to be effective and well-tolerated in the treatment of patients with long-standing systemic lupus erythematosus, offering an alternative to the B cell–depleting agent rituximab, according to a study.
13 Apr 2018
A recent study has shown that the herpes zoster (HZ) vaccine induces varicella zoster virus (VZV)-specific cellular and humoral responses in patients with rheumatic arthritis (RA).
15 Apr 2018
Compared to other tumour necrosis factor–α inhibitors (TNFi), infliximab remains superior in reducing Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at 12 weeks, results of a network meta-analysis (NMA) have shown. However, it was sensitive to inclusion of an open-label trial, and its efficacy faded at 24 weeks.